2015 CMHC - Professional Medical Education (non-CME)

Attend Professional Education Symposia

Round out your CMHC educational experience by attending Professional Education symposia focused on novel therapies and diagnostic testing. These non-certified activities are not part of the official CMHC program and are planned solely by the sponsoring organizations/companies. There are no fees to attend and meals or refreshments may be provided. View the complete schedule below. Register for the CMHC today to sign up for these activities.

Arrive Early for a Chance to Win an Apple Watch or Surface Pro!
Check in at the Registration Desk by 11:00am on Wednesday, October 21 to be entered to win.

Wednesday, October 21, 2015

Lunch Symposium (non-CME)
12:30pm - 2:00pm

Repatha™ (evolocumab): Product Overview

Presenter: James A. Underberg, MD

Sponsored by Amgen, Inc.

Wednesday, October 21, 2015

Symposium (non-CME)
2:00pm - 3:15pm

Clinical Management of Inflammatory Responses in Vascular Patients

Presenters: Marlene Grenon, MD; John Troup, PhD

Sponsored by Metagenics

Wednesday, October 21, 2015

Symposium (non-CME)
3:15pm - 4:30pm

RNA-targeting Antisense Technology Explained

Presenter: Richard S. Geary, PhD

Sponsored by Genzyme, a Sanofi company

Wednesday, October 21, 2015

Symposium (non-CME)
4:30pm - 5:45pm

Advancing Knowledge of Hypertriglyceridemia

Presenter: James M. Falko, MD

  • Epidemiology
  • Pathophysiology
  • Causes and Associated Risks
  • Assessment and Management

Sponsored by AstraZeneca

Wednesday, October 21, 2015

Reception Symposium (non-CME)
5:45pm - 7:00pm

Strategies for Effective Weight Management

Presenter: Nikhil Dhurandhar, PhD

To review the chronic nature of obesity and discuss effective weight management strategies. Also to examine the clinical benefits of targeted appetite regulation via the glucagon-like peptide-1 (GLP-1) pathway in improving weight loss in patients affected by overweight or obesity.

Sponsored by Novo Nordisk Inc.

Thursday, October 22, 2015

Symposium A (non-CME)
5:00pm - 6:00pm

Lp-PLA2 Activity Testing: An Advanced New Biomarker for CHD Management

Moderator: Michelle O'Donoghue, MD, MPH

Presenters: Mary Cushman, MD, MSc; Leslie Donato, PhD; Peter McCullough, MD, MPH

New data and perspectives will be discussed by a panel of experts and investigators focused on the new PLAC Test for Lp-PLA2 Activity.  This 60-minute curriculum includes clinical performance data based on the results of REGARDS, a large, multi-center, prospective NIH clinical study as well as Lp-PLA2 Activity data from the Mayo Clinic, and faculty roundtable discussion.

The PLAC Activity Test is the only FDA cleared test to measure Lp-PLA2 Activity, a vascular-specific inflammatory marker critical in the formation of rupture-prone plaque. The new test is intended for use as an aid in predicting risk of Coronary Heart Disease (CHD) in patients with no prior history of cardiovascular events.  The test has been validated for use on a litany of automated clinical chemistry analyzers allowing this high performance test in most all clinical laboratory settings.

Sponsored by Diadexus, Inc.

Thursday, October 22, 2015

Symposium B (non-CME)
5:00pm - 6:00pm

Understanding the Role of VASCEPA® (icosapent ethyl) as Add-on to Statins in Patients With Persistent High Triglyceride Levels (≥200 to <500 mg/dL)

Presenter: Eliot Brinton, MD

Atherosclerosis is a progressive inflammatory process leading to adverse cardiovascular outcomes. While statins have been shown to significantly reduce cardiovascular events, a high level of residual risk remains for many dyslipidemic patients. Other factors, such as high triglycerides, support the need for effective adjunctive therapy.   

Please join us for this exciting program and hear from an expert who will discuss the role and data supporting an EPA-only omega-3 PUFA as add-on to statins in patients with persistent high triglyceride levels (≥200 to <500 mg/dL).

Sponsored by Amarin Pharma, Inc.

Friday, October 23, 2015

Symposium (non-CME)
6:00pm - 7:00pm

Uncovering Generalized Lipodystrophy: Clinical Characteristics and Treatment Considerations

Presenters: Tamer Yacoub, MD

Join us to learn about generalized lipodystrophy (GL), a rare, complex, and clinically heterogeneous disorder characterized by the widespread lack or loss of adipose tissue, leading to relative leptin deficiency and associated metabolic abnormalities1. This program will review the pathophysiology of GL, the signs and symptoms for detection and diagnosis, and treatment considerations, including clinical data for the first and only FDA-approved leptin replacement therapy. A GL patient will provide the unique perspective of an individual living with the burden and challenges associate with generalized lipodystrophy.

Reference: 1. Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy: an AACE consensus statement. Endocr Pract. 2013;19(1):107-116.

Sponsored by Aegerion Pharmaceuticals

Note: Agenda & Faculty are subject to change.

View Full Program Agenda

For more information regarding sponsorship of Professional Medical Education opportunities for the 2015 Cardiometabolic Health Congress, please email info@cardiometabolichealth.org or call 877.571.4700.

Professional Medical Education Sponsors

novo nordisk
Back to 10th Annual CMHC Home